“We enjoy the shade of a mighty oak tree because someone before us planted it.”
What is the Genome-Wide Association Study (GWAS)?
- A study of genetic variations associated with a specific disease like cholangiocarcinoma
- Involves two groups of participants: people with, and people without, the disease
- A small DNA sample is obtained from each participant
- Results help researchers to develop better strategies for prevention, screening, diagnosis and treatment
Our goal is to have 100 volunteers diagnosed with cholangiocarcinoma participate in the Genome-Wide Association Study (GWAS) during the month of April
Your participation will help scientists to:
- Inspire progress and find new ways to prevent, detect, diagnose, and treat cholangiocarcinoma
- Discover important genetic risk factors for cholangiocarcinoma that may affect your family
- Identify other high risk factors for developing cholangiocarcinoma
- Find new treatments based on a patients genetic make-up
Who can participate?
There is a critical need for PATIENTS with cholangiocarcinoma to participate in the Genome-Wide Association Study (GWAS). FAMILY MEMBERS can also participate in this important research if:
- The patient is/was under the age of 50, OR
- The patient has/had a history of choledochal cysts, OR
- Another member of the patient’s immediate or extended family has also been diagnosed with cholangiocarcinoma, OR
- Multiple members of the patient’s immediate or extended family have been diagnosed with other kinds of cancer
How will you participate?
- Fill out a family history and risk factor questionnaire
- Complete forms to release health records
- Give a sample of blood; approximately 3½ tablespoons
- Donate a specimen of tissue for research use (if you are having a biopsy or surgery as part of regular medical care)
- Submit your Contact Information Form now. The Study Coordinator will follow-up within a few days.
There is a critical need for cholangiocarcinoma research.
Dear Cholangiocarcinoma Foundation Patient Community,
I write today to ask for your help.
Although this is thought to be a rare disease, cases of cholangiocarcinoma are rising in the US and worldwide. Scientists do not know what causes cholangiocarcinoma or how it can be treated effectively. Researchers are trying to find individuals who might have a high risk for developing cholangiocarcinoma so they can identify new ways to detect, diagnose, and treat it.
Mayo Clinic is one of many institutions participating in a Genome-Wide Association Study (GWAS) for cholangiocarcinoma. We compare DNA from small samples of blood from two groups: people with the disease (you) and people without (your family members or friends). This helps us to identify important genetic risk factors for cholangiocarcinoma.
There is no cost to you and it is easy to participate by donating a small sample of blood and completing a medical history questionnaire.
Lewis R. Roberts, M.B. Ch.B., Ph.D
Mayo Clinic, Division of Gastroenterology and Hepatology
Submit your Contact Information Form now. The Study Coordinator will follow up within a few days.